Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab as a Strategy to Enhance the Efficacy of Immune Checkpoint Blockade in Unresectable or Metastatic Mucosal Melanoma

Next Previous
X
Search
Trial Profile

Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab as a Strategy to Enhance the Efficacy of Immune Checkpoint Blockade in Unresectable or Metastatic Mucosal Melanoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cedazuridine/decitabine (Primary) ; Nivolumab (Primary)
  • Indications Malignant melanoma; Mouth neoplasm; Nasopharyngeal cancer; Rectal cancer; Vulvovaginal cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 26 Jun 2024 Planned primary completion date changed from 26 Jul 2024 to 26 Jul 2025.
    • 25 May 2022 Status changed from not yet recruiting to recruiting.
    • 27 Apr 2022 Planned initiation date changed from 1 Mar 2022 to 1 Mar 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top